Complete Genomics, Inc., a leading player in the genomics industry, is headquartered in the United States. Founded in 2006, the company has made significant strides in the field of DNA sequencing and analysis, positioning itself as a pioneer in whole-genome sequencing technology. With a focus on providing high-quality genomic data, Complete Genomics offers unique services that cater to both research and clinical applications. Their advanced sequencing platforms and bioinformatics solutions are designed to deliver accurate and comprehensive genomic insights, setting them apart in a competitive market. Recognised for their innovative approach, Complete Genomics has achieved notable milestones, including collaborations with major research institutions and contributions to significant genomic studies. As they continue to expand their operational reach, the company remains committed to advancing the understanding of genetics and its implications for health and disease.
How does Complete Genomics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Complete Genomics, Inc.'s score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Complete Genomics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of MGI Tech Co., Ltd., which may influence its climate commitments and reporting practices. While there are no documented reduction targets or climate pledges from Complete Genomics, Inc., it is important to note that emissions data and sustainability initiatives may be cascaded from its parent company, MGI Tech Co., Ltd. This relationship could potentially align Complete Genomics with broader corporate sustainability goals, although specific details on these initiatives are not provided. In the context of the industry, many companies are increasingly focusing on reducing their carbon footprints and committing to science-based targets. However, without specific data or commitments from Complete Genomics, it remains unclear how the company is addressing climate change and carbon emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Complete Genomics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.